

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1627
)
) LADNER, et al.) Examiner: CELSA, Bennett
)
) Serial No.: 09/896,095) Confirmation No. 8370
)
) Filed: June 29, 2001) Washington, D.C.
)
) For: DIRECTED EVOLUTION) May 8, 2002
) OF NOVEL BINDING PROTEINS)
) Docket No.: LADNER=7L



PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

S i r :

IN THE SPECIFICATION

Please replace the paragraph beginning at page 34, lines 24-27, with the following rewritten paragraph:

--BPTI Bovine pancreatic trypsin inhibitor, identical to aprotinin (Merck Index, entry 784, p.119 (SEQ ID NO:44))--

Please replace the paragraph on page 38, lines 10-18, with the following rewritten paragraph:

--A candidate IPBD should meet the following criteria:
1) a domain exists that will remain stable under the conditions of its intended use (the domain may comprise the entire protein that will be inserted, e.g. BPTI (SEQ ID NO:44), α -conotoxin GI, or CMTI-III),
2) knowledge of the amino acid sequence is obtainable, and
3) a molecule is obtainable having specific and high affinity for the IPBD, AfM (IEBD).--

Please replace the paragraph on pages 50-51, lines 13-34 and 1-8, with the following rewritten paragraph:

--Polypeptides of this size, however, have disadvantages as binding molecules. According to Olivera et al. (OLIV90a):

TECHNOLOGY

RECEIVED

12/1/02
B
J
484

152